Posted by Michael Wonder on 01 Dec 2018
New PBS listing vital to Australians living with acute myeloid leukaemia
30 November 2018 - Leukaemia Foundation CEO Mr Bill Petch has today supported the Health Minister Mr Greg Hunt’s PBS listing announcement of midostaurin (Rydapt), a targeted therapy that is considered to be an important advancement in the treatment of acute myeloid leukaemia in 25 years.
Mr Petch joined industry leaders at the Peter MacCallum Cancer Centre in Melbourne to announce midostaurin would be accessible through the PBS from December 1 for newly diagnosed Australian adults with AML who hold the FLT3-gene mutation.
The new treatment would be used as a first line therapy in combination with chemotherapy as well as a stand-alone single agent maintenance in patients responding to initial therapy.
